<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/">
<rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6684">
    <dcterms:title><![CDATA[<strong>Potential contribution of PEP carboxykinase dependent malate dismutation to the hypoxia response in C. elegans</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[C. ELEGANS]]></dcterms:subject>
    <dcterms:subject><![CDATA[NEMATODA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2023]]></dcterms:subject>
    <dcterms:creator><![CDATA[<strong>Comas Ghierra, Rosina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Romanelli Cedrez, Laura</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Salinas, Gustavo</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Nature Communications, v.14, n&deg;1, 2023. -- e3938]]></dcterms:source>
    <dcterms:publisher><![CDATA[Springer]]></dcterms:publisher>
    <dcterms:date><![CDATA[2023]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[3 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.1038/s41467-023-39510-5]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6575">
    <dcterms:title><![CDATA[<strong>Caenorhabditis elegans as a valuable model for the study of anthelmintic pharmacodynamics and drug-drug interactions : the case of ivermectin and eprinomectin</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[FARMACOLOGIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[RESISTENCIA ANTIPARASITARIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[PARASITOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[HELMINTOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[NEMATODA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2022]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Caenorhabditis elegans is a free-living nematode that has been validated for anthelmintic drug screening. However, this model has not been used to address anthelmintic dose-response-time and drug-drug interactions through matrix array methodology. Eprinomectin (EPM) and Ivermectin (IVM) are macrocyclic lactones widely used as anthelmintics. Despite being very similar, EPM and IVM are combined in commercial formulations or mixed by farmers, under the assumption that the combination would increase their efficacy. However, there is no data reported on the pharmacological evaluation of the combination of both drugs. In this study, we assessed the pharmacodynamics and drug-drug interactions of these two anthelmintic drugs. Since the action of these drugs causes worm paralysis, we used an infrared motility assay to measure EPM and IVM effects on worm movement over time. The results showed that EPM was slightly more potent than IVM, that drug potency increased with drug time exposure, and that once paralyzed, worms did not recover. Different EPM/IVM concentration ratios were used and synergy and combination sensitivity scores were determined at different exposure times, applying Highest Single Agent (HSA), Loewe additivity, Bliss and Zero Interaction Potency (ZIP) models. The results clearly indicate that there is neither synergy nor antagonism between both macrocyclic lactones. This study shows that it is more relevant to prioritize the exposure time of each individual drug than to combine them to improve their effects. The results highlight the utility of C. elegans to address pharmacodynamics studies, particularly for drug-drug interactions. Models in vitro can be integrated to facilitate preclinical and clinical translational studies and help researchers to understand drug-drug interactions and achieve rational therapeutic regimes.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Su&aacute;rez, Gonzalo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Alc&aacute;ntara, Ignacio</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?972518dae04cc6f1d53fd01909f7c2f4952184c3eedf364530afd35a4c507484cce1f86606ac8d829a37e89b7a9f837b6b0632e94efbaf9ba6abf23efe48f1dc" target="_blank"><strong>Salinas, Gustavo</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Frontiers in pharmacology, 2022.]]></dcterms:source>
    <dcterms:publisher><![CDATA[Frontiers]]></dcterms:publisher>
    <dcterms:date><![CDATA[2022]]></dcterms:date>
    <dcterms:rights><![CDATA[<p dir="ltr"><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p dir="ltr">(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p dir="ltr"><strong>La legislaci&oacute;n uruguaya protege el derecho de autor</strong>&nbsp;sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<span id="docs-internal-guid-9d2103f7-7fff-c813-00c7-2528fd4891ff"><strong>ADVERTENCIA:</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</span>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[9 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.3389/fphar.2022.984905]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6530">
    <dcterms:title><![CDATA[<strong>Structure-based boisosterism design, synthesis, biological evaluation and in silico studies of benzamide analogs as potential anthelmintics</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[BIOISOSTERISMO]]></dcterms:subject>
    <dcterms:subject><![CDATA[<a><span id="normalb" class="text3">NEMATODA</span></a>]]></dcterms:subject>
    <dcterms:subject><![CDATA[C. ELEGANS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ECHINOCOCCUS GRANULOSUS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2022]]></dcterms:subject>
    <dcterms:abstract><![CDATA[A recent screen of 67,012 compounds identified a new family of compounds with excellent nematicidal activity: the ortho-substituted benzamide families Wact-11 and Wact-12. These com pounds are active against Caenorhabditis elegans and parasitic nematodes by selectively inhibiting nematode complex II, and they display low toxicity in mammalian cells and vertebrate organisms. Although a big number of benzamides were tested against C. elegans in high-throughput screens, bioisosteres of the amide moiety were not represented in the chemical space examined. We thus iden tified an opportunity for the design, synthesis and evaluation of novel compounds, using bioisosteric replacements of the amide group present in benzamides. The compound Wact-11 was used as the reference scaffold to prepare a set of bioisosteres to be evaluated against C. elegans. Eight types of amide replacement were selected, including ester, thioamide, selenoamide, sulfonamide, alkyl thio and oxo-amides, urea and triazole. The results allowed us to perform a structure&ndash;activity relationship, highlighting the relevance of the amide group for nematicide activity. Experimental evidence was complemented with in silico structural studies over a C. elegans complex II model as a molecular target of benzamides. Importantly, compound Wact-11 was active against the flatworm Echinococcus granulosus, suggesting a previously unreported pan-anthelmintic potential for benzamides.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cv/?09f6723c0eabc2c919960c552c5adf85" target="_blank"><strong>Vairoletti , Franco</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cv/?8e4377ca77382678fd5af0d455590aa18a44e65bac89340cfafbbd41152343acd96dc3153f75f2fdf08a92578f213300543d33a6754527876021976e495c507b" target="_blank"><strong>Paulino, Margot</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cv/?11f116dbdcd0917430c764781820c3ae07133f652f4972256dc46f54fda1a3fcf8ce8ef0955ba2079acd7eb19d1ee52d88035eacfdec3666f5e20b2b35381b70" target="_blank"><strong>Mahler, Graciela</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cv/?972518dae04cc6f1d53fd01909f7c2f4952184c3eedf364530afd35a4c507484cce1f86606ac8d829a37e89b7a9f837b6b0632e94efbaf9ba6abf23efe48f1dc" target="_blank"><strong>Salinas, Gustavo</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cv/?7f698a1299f8613291da7800fd8927d1c3c8f7d6c4825f88511ab29a883aec94cfcc68b226e6ac4cfd2242415a01b6e3f1aff18fab1609921754135148cd1415" target="_blank"><strong>Saiz, Cecilia</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Molecules v.27, n&deg; 9, 2022.-- e2659]]></dcterms:source>
    <dcterms:publisher><![CDATA[MDPI]]></dcterms:publisher>
    <dcterms:date><![CDATA[2022]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><span><strong>Informaci&oacute;n sobre Derechos de Autor</strong></span></p>
<p><span>(Por favor lea este aviso antes de abrir los documentos u objetos)</span></p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho de autor</strong><span>&nbsp;sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</span></p>
<p><strong>ADVERTENCIA:</strong><span>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</span></p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.3390/molecules27092659]]></dcterms:identifier>
</rdf:Description></rdf:RDF>
